Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

Choon Kee Lee, M. Zangari, B. Barlogie, A. Fassas, F. van Rhee, R. Thertulien, G. Talamo, F. Muwalla, E. Anaissie, K. Hollmig, G. Tricot

Research output: Contribution to journalArticlepeer-review

98 Scopus citations


To evaluate the role of high-dose melphalan and autologous transplant (AT) in reversing dialysis-dependent renal failure, 59 patients still on dialysis at the time of AT were analyzed. A total of 37 patients had been on dialysis ≤6 months. A 5-year event-free and overall survival rate of all patients after AT was 24 and 36%, respectively. Of 54 patients evaluable for renal function improvement, 13 (24%) became dialysis independent at a median of 4 months after AT (range: 1-16). Dialysis duration ≤ 6 months prior to first AT and pre-transplant creatinine clearance >10 ml/min were significant for renal function recovery: 12 of 36 (33%) ≤ 6 months vs one of 18 patients (6%) > 6 months on dialysis recovered renal function; 10 of 26 (38%) with > 10 ml/min vs three of 28 (11%) with ≤ 10 ml/min of creatinine clearance (both P < 0.05). Quality of response after autotransplant was also significant: 12 of 31 (39%) being greater than partial remission after AT vs one of 21 patients (5%) attaining partial remission or less became independent of dialysis (P < 0.05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course.

Original languageEnglish (US)
Pages (from-to)823-828
Number of pages6
JournalBone Marrow Transplantation
Issue number8
StatePublished - Apr 2004


  • Multiple myeloma
  • Renal failure
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant'. Together they form a unique fingerprint.

Cite this